Projets primés en 2025
1-Dissecting the Molecular Mechanisms of SMC5/6 in Restricting Extrachromosomal DNA and Its Dysregulation in Cancer
Dr. Aurelie Diman, Department of Microbiology and Molecular Medicine UNIGE
2- Mapping Hepatomesenchymal Cells in Liver Development and Their Role in Pediatric Liver Cancer
Dr. Arnaud Bakaric, Department of Genetic Medicine and Development UNIGE
3- Preclinical proof-of-concept of a novel CCR5-targeted cancer theranostic strategy
Dr. Olivia Bejuy, HUG Diagnostic Department
4- Investigating how upstream Plk1 activators regulate cell and centrosome cycle progression and prevent cancer development
Dr Devashish Dwivedi, Department of Physiology and Metabolism UNIGE
5- Mapping the Spatial Organization of Tumor-Stroma-Immune Interactions in Pancreatic Cancer
Dr. Vassilis Genoud, HUG Department of Oncology
Projets primés en 2024
1-T cell targeting chimeric antigen receptor (CAR) regulatory T cells (Tregs) for graft-versus-host-disease (GvHD) prevention
Dre Chiara Bernardi, Departement d’Oncologie HUG
2-153sm-fapi-46 radioligand therapy with high-molar activity 153s
Dr Thierry Sora, CERN
3-Counteracting Progression Mechanisms to Overcome Immune Checkpoint Inhibitor Resistance in Bladder Cancer
Dr. Hajar El Ahanidi , Department of Pathology and Immunology UNIGE
4-Investigating the significance of a novel definition of tumora-associated macrophage polarization as an estimator of the tumor microenvironment state and prognostic tool in pancreatic ductal adenocarcinoma (PDAC)
Dr Marc Pfefferlé. Department de Pathologie et Immunologie UNIGE
5-POU5F1B, tumor microenvironment and colorectal cancer metastasis
Dre Laia Simo Riudalbas, Department of Medicine UNIGE
6-Personalized ultrahigh field MRI for prostate cancer
Dr Thomas de Perrot, Departement Diagnostique HUG
7-Investigating PD-L1 expression as predictor of response to neo-adjuvant chemotherapy in hormone receptor positive breast cancer
Dre Anita Wolfer, Departement d’Oncologie HUG
Bourse MD-PhD
Natural Language Processing Framework for Oncology Reports
Dr Johann Pignat, Departement d’Oncologie HUG